NR3C2 and chronic kidney disease: Chronic kidney disease (CKD) remains a significant global health burden despite recent advances in pharmacotherapy, including sodium‐glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists.